- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 21, Issue 2, 2015
Current Pharmaceutical Design - Volume 21, Issue 2, 2015
Volume 21, Issue 2, 2015
-
-
Role of Synovial Fibroblasts in Rheumatoid Arthritis
Authors: S. Lefevre, F.M.P. Meier, E. Neumann and U. Muller-LadnerRheumatoid arthritis (RA) is the most common autoimmune articular disorder. It is characterized by chronic inflammation and progressive joint destruction. As research traditionally focused on immune cells and cytokines, the role of stromal cells was addressed only to a limited extent. However, cell-cell interactions within the rheumatoid synovium alter the phenotype of synovial fibroblasts (SFs), which are nowadays co Read More
-
-
-
Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
More LessT cells play a role in the initiation and perpetuation of tissue inflammation that can lead to tissue destruction. With the discovery of a number of T helper subsets and their potential plasticity during disease it became clear that the T cell behaviour in autoimmune diseases is much more complex than the first Th1/Th2 concept. From experimental autoimmune arthritis models it became clear that the IL-23/IL-17 immune pathway is Read More
-
-
-
Biomarkers for Radiographic Progression in Rheumatoid Arthritis
Authors: A. Krabben, T.W.J. Huizinga and A.H.M. van der Helm-van MilTreatment of patients with rheumatoid arthritis (RA) is rarely personalized, since predictors of disease course are lacking. The severity of RA can be measured objectively by radiographic progression. The most reliable way to measure radiographic progression is in a longitudinal cohort with serial time points, scoring on a quantitative scale, with a validated scoring method and trained readers. Current models used to predict radiog Read More
-
-
-
Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis
Authors: I. Gonzalez-Alvaro, A.M. Ortiz, I.V. Seoane, R. Garcia-Vicuna, C. Martinez and R.P. GomarizThe heterogeneous nature of rheumatoid arthritis (RA) complicates early recognition and treatment. In recent years, a growing body of evidence has demonstrated that intervention during the window of opportunity can improve the response to treatment and slow— or even stop—irreversible structural changes. Advances in therapy, such as biologic agents, and changing approaches to the disease, such as the treat to target a Read More
-
-
-
Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with premature mortality, severe morbidity, and functional impairment leading to considerable financial burden for both patients and society. Since disease progression and complications can differ from one patient to another, genetic markers are of potential relevance for identifying those individuals at a higher risk of more severe disease. RA is a com Read More
-
-
-
Laboratory Biomarkers for Guiding Therapy with Methotrexate in Rheumatoid Arthritis
Methotrexate (MTX) is a first-line drug for the treatment of several rheumatic diseases. However, it is difficult to predict the response to this drug based on clinical manifestations. Although different mechanisms of action have been proposed for the antiinflammatory and immunosuppressive effects of MTX, the best characterized are blockade of the de novo synthesis of purines and pyrimidines, which inhibits DNA synthesis, a Read More
-
-
-
Response to Rituximab: Has the Original Hypothesis Been Confirmed?
Authors: Geraldine Cambridge and Inmaculada De La TorreBefore the use of rituximab, the strongest accepted evidence for an association between B-cells and rheumatoid arthritis (RA) was that clinical disease was associated with serum autoantibodies. The ability to remove B-cells with rituximab has also revealed the relative importance of the different immunological parameters that underlie the clinical symptoms of RA. First, seropositive patients have a significantly more predi Read More
-
-
-
Predictors of Response to TNF Antagonists
Authors: Eva Salgado, Jose Ramon Maneiro and Juan J. Gomez-ReinoRheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response w Read More
-
-
-
Predicting Toxicity: Biomarkers and the Value of the Patient’s Opinion
Authors: MJ Garcia de Yebenes, E Loza and L CarmonaSafety is usually a secondary endpoint in clinical trials, and most observational studies on predictors focus on response, not toxicity. Research is clearly biased towards efficacy rather than safety, probably because of the difficulty in measuring toxicity arising from lack of standardization, low statistical power, missing data, misinterpretation, and confounding variables. An extensive search revealed very few studies on toxicity Read More
-
-
-
Are Patient Self-Report Questionnaires as “Scientific” as Biomarkers in “Treat-totarget” and Prognosis in Rheumatoid Arthritis?
Authors: Theodore Pincus and Isabel CastrejonInformation from patients traditionally is regarded as “subjective,” in contrast to “objective,” “scientific” laboratory data. However, patient questionnaire scores for physical function are more significant to predict severe outcomes of rheumatoid arthritis (RA), such as work disability and mortality, than radiographs or laboratory tests. Furthermore, the 3 RA Core Data Set patient self-report measures of physical function, p Read More
-
-
-
Psychological Factors Associated with Response to Treatment in Rheumatoid Arthritis
Authors: Santiago T., Geenen R., Jacobs J.W.G. and Da Silva J.A.P.This paper presents a comprehensive review of research relating psychological domains with response to therapy in patients with rheumatoid arthritis. A holistic approach to the disease was adopted by incorporating not only disease activity but also dimensions of the impact of disease on patients’ lives. Psychological distress, including depression and anxiety, is common among patients with rheumatoid arthritis and has a s Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
